Who are ViaNautis's investors?

ViaNautis's investors include Cambridge Angels group, Oxford Investment Opportunity Network (OION), 4BIO Capital, Origin Capital, UCB Ventures.

Where is ViaNautis headquartered?

ViaNautis is headquartered in Cambridge, GB.

ViaNautis

Cambridge, GB · 44 employees on LinkedIn · 10 known investors

Find your way into ViaNautis

Paths you didn't know you had: your email and LinkedIn already hold routes to the ViaNautis team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

ViaNautis develops targeted polyNaut nanovesicle (tPNV) delivery technology to advance cell and gene therapies and genetic medicines. A UCL spin-out originally established as SomaServe in 2018, the company operates from facilities in Cambridge, UK.

Biotech Deep Tech Medical Devices

Founders & leadership

Dr Adi Hoess

Dr Ray Jupp

Dr Samuel Barker

Dr Sarah Wythe

Sam Smart

Investors · 10

Cambridge Angels grouplisted by Cambridge Angels groupCambridge · $195K – $1.9M

How we know: Cambridge Angels group's portfolio page · Not right? Tell us

Oxford Investment Opportunity Network (OION)listed by Oxford Investment Opportunity Network (OION)Oxford · $190K – $2.5M

4BIO CapitalreportedLondon

How we know: vianautis.com · Not right? Tell us

Origin CapitalreportedSingapore

How we know: vianautis.com · Not right? Tell us

UCB VenturesreportedBrussels

How we know: vianautis.com · Not right? Tell us

Also in the syndicate · 5

BGFleadCystic Fibrosis FoundationEli Lilly and CompanyMeltwindO2H

Funding

SEC filings, press & company announcements

Undisclosed amountSeries AOct 2024
4BIO Capital (lead), BGF (lead), UCB Ventures (lead), Cystic Fibrosis Foundation, Eli Lilly and Company, Meltwind, O2H, Origin Capital
Source ↗
Undisclosed amountSeries ANov 2023
4BIO Capital (lead), BGF (lead), UCB Ventures (lead), Cystic Fibrosis Foundation, Eli Lilly and Company, Meltwind, O2H, Origin Capital
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines < ViaNautisvianautis.com · Nov 2023

ViaNautis Bio Raises $25M in Series A Financingfinsmes.com · Nov 2023

Frequently asked questions

What does ViaNautis do?: ViaNautis develops targeted polyNaut nanovesicle (tPNV) delivery technology to advance cell and gene therapies and genetic medicines. A UCL spin-out originally established as SomaServe in 2018, the company operates from facilities in Cambridge, UK.
Who are ViaNautis's investors?: ViaNautis's investors include Cambridge Angels group, Oxford Investment Opportunity Network (OION), 4BIO Capital, Origin Capital, UCB Ventures.
Where is ViaNautis headquartered?: ViaNautis is headquartered in Cambridge, GB.